MedTrace Logo

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

NCT04328961 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 943

Last updated 2021-12-16

Study results available
· View outcomes & findings →

Summary

This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons with laboratory confirmed SARS-CoV-2 or clinically suspected COVID-19. Eligible participants will be enrolled and randomized to receive the intervention or placebo at the level of the household (all eligible participants in one household will receive the same intervention).

Conditions

Interventions

DRUG

Hydroxychloroquine Sulfate

Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy

DRUG

Ascorbic Acid

Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.

Sponsors & Collaborators

Principal Investigators

  • Ruanne V. Barnabas, MBChB, DPhil · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-31
Primary Completion
2020-09-24
Completion
2020-10-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04328961 on ClinicalTrials.gov